Hemophagocytic lymphohistiocytosis caused by multiple infections during primary chemotherapy for pediatric acute lymphoblastic leukemia: a case report

Front Immunol. 2024 Nov 6:15:1438378. doi: 10.3389/fimmu.2024.1438378. eCollection 2024.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder that occurs as a consequence of immune dysregulation. HLH can be primary (familial or non-familial) or secondary to infection, autoimmune disease or malignancy. Malignancy-associated HLH is often accompanied by hematologic and lymphoid neoplasms. This report describes the case of a 3-year-old girl with an initial diagnosis of acute lymphoblastic leukemia who subsequently developed HLH during primary chemotherapy. She was admitted with a pulmonary infection, and initial blood tests showed thrombocytopenia and anemia. Whole-exome sequencing of gene and whole transcriptome RNA sequencing data indicated mutations of UNC13D. The hospital course was complicated by multiple infections, altered mental status and acute respiratory distress syndrome. HLH secondary to multiple infections that achieved remission following targeted therapy with ruxolitinib, in conjunction with corticosteroids and other complementary treatments. This report provides a synopsis of the diagnostic and treatment procedures implemented in this case.

Keywords: UNC13D; hemophagocytic lymphohistiocytosis; multiple infections; pediatric acute lymphoblastic leukemia; ruxolitinib.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child, Preschool
  • Female
  • Humans
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Lymphohistiocytosis, Hemophagocytic* / drug therapy
  • Lymphohistiocytosis, Hemophagocytic* / etiology
  • Membrane Proteins
  • Mutation
  • Nitriles / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Pyrazoles
  • Pyrimidines

Substances

  • UNC13D protein, human
  • ruxolitinib
  • Nitriles
  • Membrane Proteins
  • Pyrazoles
  • Pyrimidines

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The project was supported by the Foshan self-funded scientific and technological innovation project (2220001004113) and the Doctoral Scientific Initiate Project of Shunde Women and Children’s Hospital of Guangdong Medical University (Maternity & Child Healthcare Hospital of Shunde Foshan) (2020BSQD002).